Compound class
Metabolic and mitochondrial peptides
Mitochondrial peptides, hormones and other metabolic compounds.
The compounds here range from mitochondrial peptides to hormones. MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA,1 SS-31 is another name for elamipretide,2 and vasopressin is a polypeptide hormone.3 FDA's 2026 briefing did not identify clinical studies of MOTS-c given to humans and weighs against adding it to the 503A bulks list for compounding.1 A registered phase 2a study, recruiting in 2026, plans a fixed dose of MOTS-c by subcutaneous injection once daily for 12 weeks.4 Elamipretide was granted accelerated approval in the USA in September 2025,5 as Forzinity, to improve muscle strength in patients with Barth syndrome weighing at least 30 kg.6
Metabolic 15
-
MOTS-c
Mitochondrial peptide
- Half-life
- Not stated
- Given
- Once daily under the skin, planned in one recruiting trial
- Form or status
- No product label among its sources
-
SS-31 (Elamipretide)
Mitochondrial peptide
- Half-life
- Not stated
- Given
- Not stated
- Form or status
- Has a US label
-
5-Amino-1MQ
NNMT inhibitor
- Half-life
- Not stated
- Given
- Not stated
- Form or status
- No product label among its sources
-
AICAR
AMPK activator
- Half-life
- Not stated
- Given
- Not stated
- Form or status
- No product label among its sources
-
BAM15
Mitochondrial uncoupler
- Half-life
- Not stated
- Given
- Not stated
- Form or status
- No product label among its sources
-
Calcitonin
Calcium-Regulating hormone
- Half-life
- 10.2 and 37.8 minutes, two phases after IV infusion
- Given
- Not stated
- Form or status
- Not marketed in the US
-
Clenbuterol
Beta-2 agonist
- Half-life
- Not stated
- Given
- Not stated
- Form or status
- Has a product label
-
Humanin
Mitochondrial peptide
- Half-life
- Not stated
- Given
- Not stated
- Form or status
- No product label among its sources
-
Insulin
Anabolic peptide hormone
- Half-life
- About 1.5 hours under the skin (Humulin R); 1 hour (Humalog)
- Given
- With meals: Humalog just before, Humulin R 30 to 45 minutes before (Humalog label)
- Form or status
- Has a US label
-
Levothyroxine (T4)
Thyroid hormone
- Half-life
- Not stated
- Given
- Not stated
- Form or status
- Has a US label
-
Salmon Calcitonin
Calcium-Regulating hormone
- Half-life
- About 18 minutes
- Given
- Not stated
- Form or status
- Has a US label
-
Tesofensine
Triple reuptake inhibitor
- Half-life
- Not stated
- Given
- Once daily in studies
- Form or status
- No product label among its sources
-
Tetrathiomolybdate
Copper chelator
- Half-life
- Not stated
- Given
- Not stated
- Form or status
- No product label among its sources
-
Thyrotropin-Releasing Hormone (TRH)
Hypothalamic releasing hormone
- Half-life
- Not stated
- Given
- Not stated
- Form or status
- Not stated
-
Vasopressin
Posterior pituitary hormone
- Half-life
- Not stated
- Given
- Not stated
- Form or status
- Has a US label
Supplements 1
Where some figures in the list come from
- Calcitonin: this row is human calcitonin; salmon calcitonin has its own row. Cibacalcin, a human calcitonin injection approved in the US in 1986, is listed as discontinued.7
Guides 6
- 5-Amino-1MQ dosage: oral or injected formsMouse doses by study, the vial and dose shares people log in Milligram, and a 50 mg vial with 3 mL worked out on a U-100 syringe.
- AICAR dosage: trial infusions and vial arithmeticAICAR (acadesine) infusion doses from human trials, one trial's IV dilution, and syringe arithmetic only, as no powder-vial preparation is sourced.
- MOTS-c dosage: mixing 10 and 40 mg vials, in unitsFDA lists MOTS-c in no approved drug, and the one registered trial states no dose amount. What people log, how 10 and 40 mg vials map to U-100 units.
- NAD+ injection dosage: mixing 500 and 1,000 mg vialsWhat trials gave NAD+ by vein and into muscle, what a subcutaneous trial plans, and how 500 and 1,000 mg vials map to syringe units.
- SS-31 dosage: the labelled solution and logged powder vialsElamipretide doses on the US label, a ready-made solution, and in trials, plus syringe arithmetic for the 10 and 50 mg powder vials logged in Milligram.
- Tesofensine dosage: what sources sayTesofensine doses by trial arm, 0.125 to 1.0 mg once daily for 14 to 24 weeks, plus Tesomet arms and a 23-day phase 1 loading dose study.
Calculators 3
- MOTS-c reconstitution calculator: 10 and 40 mg vialsUnits on a U-100 syringe for MOTS-c: enter your vial, water and dose, or print the chart for 10, 20 and 40 mg vials.
- NAD+ reconstitution calculator: 500 and 1,000 mg vialsUnits on a U-100 syringe for NAD+: enter your vial, water and dose, or print the chart for 100, 500 and 1,000 mg vials.
- SS-31 dosage calculator: vials, water and unitsUnits on a U-100 syringe for SS-31 (Elamipretide): enter your vial, water and dose, or print the chart for 10 and 50 mg vials.
Logged in Milligram
Share of people who logged a dose in Milligram in the 90 days to 15 November 2026 who logged each compound.
MOTS-c, how often
NAD+, how often
SS-31 (Elamipretide), how often
5-Amino-1MQ, how often
How often: among people with three or more logged doses, by the average gap between their doses.
Aggregated and anonymous, shares of people only. Each compound not listed: too few people logged it to show a share. It describes what people set up in the app, not advice on what to take.
References 15
- US Food and Drug Administration. Evaluation of MOTS-c-related bulk drug substances (MOTS-c (free base) and MOTS-c acetate) for inclusion on the 503A bulk drug substances list. FDA briefing document, Pharmacy Compounding Advisory Committee, July 23-24, 2026 (dated 11 May 2026). 2026. fda.gov
- Reid Thompson W, Hornby B, Manuel R, et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. 2021. PMC7935714
- Par Health USA, LLC. Vasostrict (vasopressin) label, version 49. 2026. DailyMed label
- Hudson Biotech. MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity. ClinicalTrials.gov NCT07505745, 2026. NCT07505745
- Shirley M. Elamipretide: First Approval. 2026. PMID 41335372
- Forzinity (elamipretide hydrochloride) injection. US prescribing information, DailyMed. DailyMed label
- US Food and Drug Administration. Drugs@FDA: NDA 018470, Cibacalcin (calcitonin human). Read 19 November 2026. Drugs@FDA
- Antonin KH, et al. Colonic absorption of human calcitonin in man. Clin Sci (Lond) 1992. PMID 1335402
- Spiropent 0,02 mg Tabletten (clenbuterol hydrochloride). Fachinformation (German summary of product characteristics), Hikma document spc-de-spiropent-230901. German SmPC
- Eli Lilly and Company. Humulin R (insulin human) injection. US prescribing information, DailyMed record version 35, 2026. DailyMed label
- Eli Lilly and Company. Humalog (insulin lispro) injection. US prescribing information, DailyMed record version 87, 2026. DailyMed label
- AbbVie Inc. Synthroid (levothyroxine sodium) tablets. US prescribing information, DailyMed label version 1537, 2024. DailyMed label (Synthroid)
- Par Health USA, LLC. Calcitonin salmon nasal solution. US prescribing information, DailyMed record version 22, 2026. DailyMed label (nasal solution)
- Mylan Institutional LLC. Miacalcin (calcitonin salmon) injection, for subcutaneous or intramuscular use. US prescribing information, DailyMed record version 9. DailyMed label (injection)
- Saniona. A Study to Examine the Effect of Tesofensine and Metoprolol on the 24-hour Mean Heart Rate. ClinicalTrials.gov NCT03488719. NCT03488719
Each figure is as the compound's own sources give it, numbered under References. Where they give none, the list says not stated. The half-life the app draws levels with can differ. Reviewed 17 November 2026.